Saturday, 18 July 2026 · Europe
EUR/USD 1.143 EUR/GBP 0.851 EUR/CHF 0.9228 EUR/PLN 4.347 All rates →
Sign in · Join
EUROPES The European Report
European Edition Saturday, 18 July 2026
LATEST
Longevity

Qihan scores FDA ‘triple crown’ for cell therapy

Qihan scores FDA ‘triple crown’ for cell therapy
Longevity.Technology

Chinese biotech’s universal CAR-T therapy secures FDA’s three top expedited designations, potentially accelerating its path to patients. Qihan Biotech has reached a landmark moment in its journey to bring next-generation cell therapies to patients. The Hangzhou-based company has announced that its lead candidate, QT-019B, has received both Regenerative Medicine Advanced Therapy (RMAT) designation and Breakthrough […] The post Qihan scores FDA ‘triple crown’ for cell therapy appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.

Read full coverage at Longevity.Technology →

More from Longevity